Form 10-Q FATE THERAPEUTICS INC For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street wavers as Federal Reserve holds key rate steady, pending more data
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- Oracle sets $225 billion revenue target for FY30 at investor day
- S&P Global explores potential separation of Capital IQ business
- SpaceX stock drops amid spaceport lawsuit, debt concerns
- Rivian shares slip ahead of Thursday earnings release
- Moderna stock rises on latest cancer vaccine data publication
Fate Therapeutics (FATE) Tops Q2 EPS by 7c
August 12, 2014 4:28 PM EDTFate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More


